We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Expert Opinion / Interview · December 07, 2016

ESMO 2016: Recap of Metastatic Breast Cancer

Interview with
Lee S. Schwartzberg MD, FACP
Lillie D. Shockney RN, BS, MAS, HON-ONN-CG
Reshma L. Mahtani DO

 

Additional Info

  1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738-1748.
  2. Finn RS, Martin M, Rugo HS, et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 507.
  3. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936.
  4. Royce M, Villanueva C, Ozgurogluc M, et al. BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (BC). Paper presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 2220.
  5. Rugo HS, Seneviratne L, Beck JT, et al. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): Results of the SWISH trial. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 525.
  6. Rugo HS, Barve A, Waller CF, et al. Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab. Paper presented at: ESMO 2016 Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract LBA 16.
  7. Reinbolt RE, Tolliver K, Abdel-Rasoul M, et al. Decision impact analysis of comprehensive genomic profiling (CGP) in advanced breast cancer: A prospective study. Paper presented at: 2016 Annual Meeting of the American Society of Clinical Oncology; June 3-7, 2016; Chicago, IL. Abstract 11578.

Disclosure statements are available on the authors' profiles:

Further Reading